Mavacaptan Camzyos 2.5 Mg Capsules (Mavacamten)

Description

Introduction Of Mavacamten 2.5mg Capsule:

Camzyos, generic mavacamten, is the first approved cardiac myosin inhibitor, used to treat adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). It works by reducing excessive contraction of heart muscle, improving symptoms and activity tolerance

Composition / Salt:

• Active Molecule: Mavacamten
• Drug Class: Cardiac myosin inhibitor; selectively modulates myosin heads to alleviate hypercontractility
• Formulation: Oral capsules
• Approved For: Adults with NYHA Class II–III obstructive HCM

Dosage & Administration:

• Usual Dose: Once-daily oral dose (strength personalized based on individual patient assessment; typical dosing starts at 5 mg/day and is titrated by echocardiogram)

Monitoring:

• Requires specialized titration based on echocardiographic findings
• Available only through the Camzyos REMS Program, which mandates certified providers, pharmacies, and patients

Side Effects Of Mavacamten 2.5mg Capsule:

Common:

• Dizziness, syncope
• Headache, fatigue
• Shortness of breath

Serious Risk:

• Heart failure due to systolic dysfunction

Warnings & Precautions Of Mavacamten 2.5mg Capsule:

• Heart failure risk: performance must be monitored closely; discontinue if LVEF becomes dangerously low
• REMS program: Only accessible via certified clinicians, pharmacies, and patients, with regular echocardiographic monitoring

Contact Us